ALLMedicine™ Hypertrophic Cardiomyopathy Center

Aug 3rd, 2020 - Noonan syndrome is a relatively common genetic disorder and the second most common cause of congenital heart disease after trisomy 21. The spectrum of cardiac anomalies in Noonan syndrome typically involves pulmonary valve stenosis occasionally in...

Aug 2nd, 2020 - Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?|2020|Maron BJ,Rowin EJ,Maron MS,|

Aug 2nd, 2020 - A case of late-detected Pheochromocytoma in a young patient with resistant hypertension and hypertrophic cardiomyopathy.|2020|Alamri A,Oriez C,Brenier M,Voican A,Banu I,|

Aug 1st, 2020 - Myocardial fibrosis (MF) is considered a result of microvascular dysfunction in patients with hypertrophic cardiomyopathy (HCM). Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), capable to degrade collagen, directly participat...

Jul 31st, 2020 - Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardio...

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Dec 18th, 2018 - Myocardial diseases are associated with an increased risk of potentially fatal cardiac arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compact...

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012)　- Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

Aug 3rd, 2020 - Noonan syndrome is a relatively common genetic disorder and the second most common cause of congenital heart disease after trisomy 21. The spectrum of cardiac anomalies in Noonan syndrome typically involves pulmonary valve stenosis occasionally in...

Aug 2nd, 2020 - Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?|2020|Maron BJ,Rowin EJ,Maron MS,|

Aug 2nd, 2020 - A case of late-detected Pheochromocytoma in a young patient with resistant hypertension and hypertrophic cardiomyopathy.|2020|Alamri A,Oriez C,Brenier M,Voican A,Banu I,|

Aug 1st, 2020 - Myocardial fibrosis (MF) is considered a result of microvascular dysfunction in patients with hypertrophic cardiomyopathy (HCM). Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), capable to degrade collagen, directly participat...

Jul 31st, 2020 - Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardio...

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

May 6th, 2019 - Patient-reported outcomes have been collected in only 14% of atrial fibrillation studies on Clinicaltrials.gov. (JACC: Clinical Electrophysiology) Novel cardiac myosin modulator mavacamten met its primary endpoint in obstructive hypertrophic cardi...

Mar 16th, 2019 - NEW ORLEANS – The portability, convenience, and the mobile health care that wearable technology achieve is clearly being described in the Apple Heart Study, Matthew W. Martinez, MD, medical director of the Sports Cardiology and Hypertrophic Cardio.

Feb 12th, 2019 - SNOWMASS, COLO. – Cardiac MRI is the go-to tiebreaker when uncertainty exists as to whether cardiac remodeling in a competitive athlete is physiological or pathological, according to Matthew W.

Feb 6th, 2019 - Another fatty acid β-oxidation inhibitor failed to boost exercise capacity or ease symptoms in non-obstructive hypertrophic cardiomyopathy (HCM) in a small placebo-controlled trial. Study participants who were randomized to trimetazidine had a sma...